<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01743820</url>
  </required_header>
  <id_info>
    <org_study_id>MEG001</org_study_id>
    <nct_id>NCT01743820</nct_id>
    <nct_alias>NCT02011555</nct_alias>
  </id_info>
  <brief_title>Phase2a Primaquine Dose Escalation Study</brief_title>
  <official_title>Phase 2a Dose Escalation Study of the Efficacy, Safety, and Pharmacokinetics of Low Dose Primaquine for Gametocytocidal Activity Against P. Falciparum in Sub-Saharan Africa and South East Asia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Malaria Research and Training Center, Bamako, Mali</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shoklo Malaria Research Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mahidol Oxford Tropical Medicine Research Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wellcome Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of low
      single-dose primaquine for gametocidal activity against P.falciparum among adult
      glucose-6-phosphate dehydrogenase (G6PD)-normal malaria patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mosquito infectivity assessed through membrane feeding</measure>
    <time_frame>7 days</time_frame>
    <description>Baseline, Days 1, 2, 7</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>gametocyte prevalence and density</measure>
    <time_frame>28 days</time_frame>
    <description>Baseline, Hours 2, 6, 12, 24, Days 2, 3, 7, 14, 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>primaquine pharmacokinetics - area under the curve (AUC) of parent drug and metabolite</measure>
    <time_frame>24 hours</time_frame>
    <description>Hours 1, 2, 3, 4, 6, 8, 12, 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>asexual parasite prevalence and density</measure>
    <time_frame>28 days</time_frame>
    <description>Baseline, Hours 2, 6, 12, 24, Days 2, 3, 7, 14, 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety measurements including hemoglobin and signs of hemolysis</measure>
    <time_frame>28 days</time_frame>
    <description>Baseline, Days 1, 2, 3, 7, 14, 28</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>dihydroartemisinin-piperaquine only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dihydroartemisinin -piperaquine (DP) only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DP and 0.125 mg/kg primaquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DP and single dose oral 0.125 mg/kg primaquine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DP and 0.5 mg/kg primaquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DP and single dose oral 0.5 mg/kg primaquine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DP and 0.25 mg/kg primaquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DP and a single dose oral 0.25 mg/kg primaquine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DP and 0.0625 mg/kg primaquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DP and a single dose oral 0.0625 mg/kg primaquine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dihydroartemisinin-piperaquine</intervention_name>
    <arm_group_label>dihydroartemisinin-piperaquine only</arm_group_label>
    <arm_group_label>DP and 0.125 mg/kg primaquine</arm_group_label>
    <arm_group_label>DP and 0.5 mg/kg primaquine</arm_group_label>
    <arm_group_label>DP and 0.25 mg/kg primaquine</arm_group_label>
    <arm_group_label>DP and 0.0625 mg/kg primaquine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.125 mg/kg Primaquine</intervention_name>
    <arm_group_label>DP and 0.125 mg/kg primaquine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.5 mg/kg Primaquine</intervention_name>
    <arm_group_label>DP and 0.5 mg/kg primaquine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.25 mg/kg Primaquine</intervention_name>
    <arm_group_label>DP and 0.25 mg/kg primaquine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.0625 mg/kg Primaquine</intervention_name>
    <arm_group_label>DP and 0.0625 mg/kg primaquine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male

          -  Age &gt;= 18 years and &lt; 50 years

          -  Malaria blood thick film positive

          -  Presence of gametocytes on thick blood film

          -  Agrees to admission to study ward for 26 hours post diagnosis and available for follow
             up visits

          -  No allergies to study drugs

          -  Hemoglobin &gt;= 8 g/dl

          -  No evidence of severe or chronic disease

          -  Written, informed consent
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roland Gosling, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alassane Dicko, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Malaria Research and Training Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fran√ßois Nosten, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shoklo Malaria Research Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Malaria Research and Training Centre</name>
      <address>
        <city>Bamako</city>
        <country>Mali</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mali</country>
  </location_countries>
  <removed_countries>
    <country>Thailand</country>
  </removed_countries>
  <reference>
    <citation>Gosling RD, Okell L, Mosha J, Chandramohan D. The role of antimalarial treatment in the elimination of malaria. Clin Microbiol Infect. 2011 Nov;17(11):1617-23. doi: 10.1111/j.1469-0691.2011.03660.x. Epub 2011 Sep 26. Review.</citation>
    <PMID>21951597</PMID>
  </reference>
  <reference>
    <citation>Baird JK, Schwartz E, Hoffman SL. Prevention and treatment of vivax malaria. Curr Infect Dis Rep. 2007 Jan;9(1):39-46.</citation>
    <PMID>17254503</PMID>
  </reference>
  <reference>
    <citation>WHO (2011) World Malaria Report 2011. Geneva: World Health Organization.</citation>
  </reference>
  <reference>
    <citation>WHO (2010) Guidelines for the treatment of malaria, Second edition. Geneva: World Health Organization</citation>
  </reference>
  <reference>
    <citation>El-Sayed B, El-Zaki SE, Babiker H, Gadalla N, Ageep T, Mansour F, Baraka O, Milligan P, Babiker A. A randomized open-label trial of artesunate- sulfadoxine-pyrimethamine with or without primaquine for elimination of sub-microscopic P. falciparum parasitaemia and gametocyte carriage in eastern Sudan. PLoS One. 2007 Dec 12;2(12):e1311.</citation>
    <PMID>18074034</PMID>
  </reference>
  <reference>
    <citation>Shekalaghe SA, ter Braak R, Daou M, Kavishe R, van den Bijllaardt W, van den Bosch S, Koenderink JB, Luty AJ, Whitty CJ, Drakeley C, Sauerwein RW, Bousema T. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals. Antimicrob Agents Chemother. 2010 May;54(5):1762-8. doi: 10.1128/AAC.01135-09. Epub 2010 Mar 1.</citation>
    <PMID>20194698</PMID>
  </reference>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2012</study_first_submitted>
  <study_first_submitted_qc>December 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2012</study_first_posted>
  <last_update_submitted>January 16, 2015</last_update_submitted>
  <last_update_submitted_qc>January 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primaquine</mesh_term>
    <mesh_term>Piperaquine</mesh_term>
    <mesh_term>Dihydroartemisinin</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

